<DOC>
	<DOCNO>NCT02453048</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity high dose formulation new live attenuate vaccine , BPZE1 , intend prevent Bordetella pertussis nasopharyngeal colonization pertussis disease , investigate whether high dos BPZE1 induce live vaccine colonize subject ' nasopharynx . The study Phase Ib ( high dose ) , single centre , dose-escalating , placebo-controlled study live attenuate B. pertussis strain BPZE1 give single intranasal dose healthy adult volunteer .</brief_summary>
	<brief_title>Study BPZE1 ( High Dose ) Nasal Live Attenuated B. Pertussis Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy individual 18 32 year age , vaccinate unvaccinated acellular pertussis vaccine . 2 . Female subject child bear potential must willing ensure use highly efficient method contraception study ( e.g . contraceptive pill , intrauterine contraceptive device ) . 3 . Informed consent form ( ICF ) sign subject . 4 . Subject shall able attend schedule visit understand comply study procedure . 1 . Individual PT and/or PRN serum IgG antibodies ≥20 International units/ml ( IU/ml ) . NOTE ! One control group PRN serum IgG antibody ≥ 20 IU/ml include . 2 . Vaccinated study vaccine Child Innovac study ( EudraCT number 201001993611 ) . 3 . Pregnant lactating woman . Pregnancy plan avoid study use effective contraceptive method . 4 . Blood pressure rest ≥ 150/90 mm Hg screening . 5 . Heart rate rest ≥ 80 bpm screening . 6 . Respiratory rate rest ≥ 20/minute screening . 7 . Unwillingness refrain use nicotine product screen day 28 . 8 . Use narcotic drug and/or history drug/alcohol abuse past 2 year prior screen 9 . The subject donate blood suffer blood loss least 450 ml ( 1 unit blood ) within 60 day prior screen donate plasma within 14 day prior screen . 10 . Receipt immunoglobulin , blood derive product , systemic corticosteroid immunosuppressant drug within 90 day prior day 0 . 11 . Asthma chronic respiratory problem . 12 . Use corticosteroids respiratory tract ( e.g . nasal steroid , inhaled steroid ) 30 day prior day 0 . 13 . Receipt vaccine within last 30 day prior day 0 plan vaccination next 30 day day 0 . 14 . Known hypersensitivity component study vaccine . 15 . Current participation clinical trial participation ( whole study ) clinical trial previous 3 month prior day 0 . 16 . Inability adhere protocol , include plan move area . 17 . Family ( first degree ) history congenital hereditary immunodeficiency . 18 . Past present infection HIV , hepatitis B C. 19 . Chronic condition require ongoing active medical intervention , diabetes mellitus cardiovascular disease . 20 . Any autoimmune immunodeficiency disease/condition ( inherited iatrogenic ) . 21 . Any medical condition , opinion investigator , might interfere evaluation study objective might affect safety individual , e.g . evolve encephalopathy attributable another identifiable cause within 7 day administration previous dose vaccine , hospitalization due major depression history suicidal attempt . 22 . Abnormal laboratory value outside limit normal value screen laboratory clinical significance discretion investigator . 23 . Person frequent contact child less 1 year age ( parent , childcare worker , nurse , etc ) residence household person know immunodeficiency include person immunosuppressant therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>32 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Colonization</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immune response</keyword>
	<keyword>BPZE1</keyword>
	<keyword>Infection</keyword>
	<keyword>Bordetella pertussis</keyword>
	<keyword>B. pertussis</keyword>
	<keyword>respiratory Tract Infection</keyword>
</DOC>